On Friday, a Centers for Disease Control and Prevention advisory committee reaffirmed that its recommendation for use of the Johnson & Johnson coronavirus vaccine. According to the Committee, the benefits outweighed the risks of a rare blood-clot condition.
But the Committee voted 10 to 4 with one abstention to advise the U.S. Food and Drug Administration (FDA) and the CDC to resume use of the vaccine without any conditions.
The J&J vaccine use was put on hold last week, following reports of rare blood-clot conditions in six people, including one fatality. Dr. Anthony Fauci, President Joe Biden’s chief medical adviser, had expected that the U.S. use of the vaccine would resume as soon as Friday, perhaps with new restrictions.
However, the FDA is expected to include label warning on the J&J vaccine to women under the age of 50.